Stock Events

Stock Events

Lumos Pharma

$4.34

12

+$0+0% Wednesday 21:00

Statistics

Day High

4.34

Day Low

4.34

52W High

4.58

52W Low

1.37

Volume

390,873

Avg. Volume

96,073

Mkt Cap

0

P/E Ratio

-

Dividend Yield

-

Dividend

-

Earnings

6MarExpected

Q2 2023

Q3 2023

Q4 2023

Q1 2024

Q2 2024

Q3 2024

Q4 2024

-1.29

-1.01

-0.73

-0.45

Expected EPS

-0.446675

Actual EPS

N/A

Financials

-1,511.68%Profit Margin

Unprofitable

2018

2019

2020

2021

2022

2023

2.88MRevenue

-43.49MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow LUMO. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

Biogen focuses on developing therapies for neurological and neurodegenerative diseases, overlapping with Lumos Pharma's interest in rare diseases.

Vertex Pharmaceuticals

Vertex Pharmaceuticals engages in creating transformative medicines for serious diseases, directly competing in the rare disease market.

Sarepta Therapeutics

Sarepta Therapeutics specializes in the discovery and development of RNA-based therapeutics for rare diseases, closely aligning with Lumos Pharma's focus.

Biomarin Pharmaceutical

BioMarin Pharmaceutical develops and commercializes innovative biopharmaceuticals for rare diseases and medical conditions, making it a direct competitor.

Alnylam Pharmaceuticals

Alnylam Pharmaceuticals works on RNAi therapeutics for the treatment of rare genetic diseases, competing in the same niche as Lumos Pharma.

Regeneron Pharmaceuticals

Regeneron Pharmaceuticals is involved in developing and commercializing medicines for serious medical conditions, including rare diseases.

PTC Therapeutics

PTC Therapeutics focuses on the discovery and commercialization of novel medicines that target rare disorders, directly competing with Lumos Pharma.

Ionis Pharmaceuticals

Ionis Pharmaceuticals specializes in RNA-targeted drug discovery and development, making it a competitor in the rare disease sector.

CRISPR Therapeutics

CRISPR Therapeutics is engaged in the development of gene-based therapies for serious diseases, including rare genetic disorders, competing in the same field.

Novo Nordisk is a global healthcare company with a strong focus on diabetes and other serious chronic conditions, but its interest in biopharmaceuticals for rare diseases places it as a broader competitor.

About

Health Technology

Biotechnology

Pharmaceuticals: Major

Manufacturing

Pharmaceutical Preparation Manufacturing

Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone secretagogue ibutamoren, which is in Phase 2 clinical trial for the treatment of pediatric growth hormone deficiency and other rare endocrine disorders. The company is headquartered in Austin, Texas.

Show more...

CEO

Employees

33

Country

United States

ISIN

US55028X1090

Listings

0 Comments

Share your thoughts

FAQ

What is Lumos Pharma stock price today?▼

The current price of LUMO is $4.34 USD — it has increased by +0% in the past 24 hours. Watch Lumos Pharma stock price performance more closely on the chart.

What is Lumos Pharma stock ticker?▼

Depending on the exchange, the stock ticker may vary. For instance, on exchange Lumos Pharma stocks are traded under the ticker LUMO.

What is Lumos Pharma revenue for the last year?▼

Lumos Pharma revenue for the last year amounts to 2.88M USD.

What is Lumos Pharma net income for the last year?▼

LUMO net income for the last year is -43.49M USD.

How many employees does Lumos Pharma have?▼

As of April 17, 2026, the company has 33 employees.

In which sector is Lumos Pharma located?▼

Lumos Pharma operates in the Technology sector.

When did Lumos Pharma complete a stock split?▼

The last stock split for Lumos Pharma was on March 19, 2020 with a ratio of 1:9.